Development and validation of liquid chromatography–mass spectrometry method for the determination of telmisartan in human plasma

Chen, Ben-Mei; Liang, Yi‐Zeng; Wang, Yali; Deng, Fang; Zhou, Panyue; Guo, Fang-Qiu; Huang, Lan-Fang

doi:10.1016/j.aca.2005.03.004

Cited by 47 publications

(31 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies recently suggest that the effects of telmisartan are mediated via not only blockade of AT1R but also activation of peroxisome proliferators-activated receptor (PPAR)-γ [5]. The literature reveals that there are a plethora of analytical methods reported for the quantitative determination of TEL in bulk, pharmaceutical formulations and biomatrices mainly based on high performance-liquid chromatography (HPLC) [6][7][8][9][10] and liquid chromatography-tandem mass spectrometry (LC/MS/MS) [11][12][13]. Other methods developed for the determination of telmisartan include immunoassay [14].…”

Section: Introductionmentioning

confidence: 99%

New Highly-Sensitive Ultra-Performance Liquid Chromatography - Mass Spectrometry Method for Quantification of Telmisartan in Human Plasma

Wani¹,

Zargar²

2015

Trop. J. Pharm Res

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

New Highly-Sensitive Ultra-Performance Liquid Chromatography - Mass Spectrometry Method for Quantification of Telmisartan in Human Plasma

Wani¹,

Zargar²

2015

Trop. J. Pharm Res

View full text Add to dashboard Cite

“…Literature review revealed that there are various methods for determination of Telmisartan and Atorvastatin calcium, individually and in combination with other drugs. The majority of methods reported are liquid chromatography coupled to UV 5,6 , fluorimetric 7 electrochemical 8,9 , or mass spectrometry detection [10][11][12][13] but some determinations were also performed by thin layer 14,15 , micellar electrokinetic 16 and gas chromatography 17,18 or spectrophotometry 19,20 . A LC method for the assay and related substances of Atorvastatin is also reported in the European Pharmacopoeia 21 .…”

Section: Introductionmentioning

confidence: 99%

Simultaneous Determination of Atorvastatin Calcium and Telmisartan in Pharmaceutical Formulations by Reverse Phase-High Performance Liquid Chromatography

Charde¹,

Gupta²,

Chakole³

2012

Int J Pharmceut Chem

View full text Add to dashboard Cite

ABSTRACT:A simple, sensitive and reproducible reverse-phase high performance liquid chromatographic (RP-HPLC) method has been developed for simultaneous quantitative estimation of Atorvastatin calcium (ATOR) and Telmisartan (TELM) in the pharmaceutical formulations. Chromatographic separation was achieved on a 250 × 4.6 mm, 5µ, Waters symmetry column. The flow rate was 1ml/min and eluent was monitored by absorbance at 267 nm using a mixture of Methanol and Acetonitrile (pH 3.0±0.01) in the ratio of 25:75 (v/v). The retention time of Atorvastatin calcium and Telmisartan was found to be 5.6 and 8.2 min respectively. Calibration plots were linear in the concentration range of 5-25 µg/ml for Atorvastatin calcium and 10-50 µg/ml for Telmisartan with correlation coefficient (R 2 ) 0.999 respectively. The proposed method was validated by testing its linearity, recovery, specificity, system suitability, precision (Interday, intraday, analyst and instrument precision), robustness and LOD/LOQ values and it was successfully employed for the determination of Atorvastatin calcium and Telmisartan in pharmaceutical tablet formulations.

show abstract

“…TELMI blocks the vasoconstrictor and aldosterone secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland [2,3]. TELMI has been estimated by various methods like spectrophotometric [4], HPLC [5,6], HPTLC [7][8][9][10], and LC-MS [11,12] in pharmaceutical formulations and biological fluids.…”

Section: Introductionmentioning

confidence: 99%

Normal and Reversed-Phase HPTLC Methods for Simultaneous Estimation of Telmisartan and Metoprolol Succinate in Pharmaceutical Formulation

Nawale

Shirkhedkar

Surana

et al. 2012

ISRN Analytical Chemistry

View full text Add to dashboard Cite

Two simple precise normal-phase (Method I) and reversed-phase (Method II) HPTLC/densitometry method have been developed for simultaneous determination of telmisartan and metoprolol succinate in bulk and in combined tablet formulation. Method I was developed with aluminium plates precoated with silica gel 60F 254 S, and toluene : propanol : methanol : triethylamine (8 : 1 : 1 : 0.5 v/v) was used as as mobile phase. Method II was carried out using aluminium coated with RP-18 silica gel 60 F 254 S HPTLC plates using methanol : water : triethylamine (6 : 4 : 0.5 v/v) as mobile phase. Both analyses were scanned with a densitometer at 242 nm. In Method I, good separation and resolution of drugs were achieved with R f values 0.45 ± 0.02 (telmisartan) and 0.70 ± 0.02 (metoprolol), while in Method II, telmisartan and metoprolol showed R f values 0.55 ± 0.02 and 0.41 ± 0.02, respectively. These methods can be used in routine pharmaceutical analysis.

show abstract

Development and validation of liquid chromatography–mass spectrometry method for the determination of telmisartan in human plasma

Cited by 47 publications

References 22 publications

New Highly-Sensitive Ultra-Performance Liquid Chromatography - Mass Spectrometry Method for Quantification of Telmisartan in Human Plasma

New Highly-Sensitive Ultra-Performance Liquid Chromatography - Mass Spectrometry Method for Quantification of Telmisartan in Human Plasma

Simultaneous Determination of Atorvastatin Calcium and Telmisartan in Pharmaceutical Formulations by Reverse Phase-High Performance Liquid Chromatography

Normal and Reversed-Phase HPTLC Methods for Simultaneous Estimation of Telmisartan and Metoprolol Succinate in Pharmaceutical Formulation

Contact Info

Product

Resources

About